Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBluecross Idaho Prior Auth Guidelines | OpenPayer
    Ask Trek AI about this page
    CurrentBluecross IdahoPolicy MP 5.01.501

    Guidelines for Prior Authorization of Pharmacologic Therapies

    Customize your policy alerts

    Sign up for Bluecross Idaho Policy MP 5.01.501 alerts

    Get alerted when Policy MP 5.01.501 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Blue Cross of Idaho requirements and criteria for prior authorization, formulary exceptions, and evaluation of on- and off-label pharmacologic therapies for members covered under BCI benefit plans.

    Policy Summary
    PayerBluecross Idaho
    PolicyGuidelines for Prior Authorization of Pharmacologic Therapies
    Policy CodePolicy MP 5.01.501
    Change TypeNo material changes
    Effective DateDec 18, 2025
    Last ReviewDec 18, 2025
    Next Review DateDec 18, 2025
    Key ActionSubmit prior authorization for any medication on the Blue Cross of Idaho PA list.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    PA listrequire prior authorization
    1 & 2ANCCN oncologic recommendations
    2 studiesmin evidence for off-label
    Multiplereference sources

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage and Medical Necessity Criteria

    Coverage criteria

    Coverage and prior authorization determinations are made when criteria from the member contract and recognized clinical evidence sources are satisfied.

    General prior authorization and medical necessity: All medications on the BCI prior authorization list require prior authorization and appropriate clinical documentation per the member-specific benefit plan.

    Sources used include FDA, MPS, InterQual, PBM criteria, NCCN, AHFS, Facts & Comparisons, and peer-reviewed literature.

    Formulary exception criteria: When contractually allowed, formulary exception requests must meet all of the following: (1) the requested medication is being used for an FDA‑approved indication; AND (2) the medication and dose are medically necessary and appropriate for the condition; AND (3) clinical documentation establishes that all available therapeutic equivalents on the formulary (or other medically appropriate medications if no equivalents exist) have either been ineffective or are reasonably expected to cause harm; AND (4) the requested drug meets any applicable utilization management requirements for its therapeutic class.

    Applies only to contracts permitting non‑formulary coverage (e.g., Qualified Health Plans).

    Off‑label use coverage: Off‑label uses (including dosing beyond FDA limits and polypharmacy) may be considered medically necessary when the use meets BCI medical necessity standards AND is recognized as appropriate by listed sources (NCCN, AHFS, Facts & Comparisons with evidence level A/B/C/G) OR when not included in those resources is supported by at least two peer‑reviewed scientific studies demonstrating efficacy and safety.minimum: 2 peer‑reviewed studies when not in listed sources

    Effectiveness determination prioritizes scientific evidence, then professional standards, then expert opinion; more cost‑effective alternatives may require trial and failure unless contraindicated.

    Oncologic drug evaluation: Oncologic drug uses are evaluated per NCCN; NCCN category 1 or 2A recommendations may be considered medically necessary when appropriately applied; lower category recommendations (e.g., 2B and below) are considered investigational.NCCN category 1 or 2A

    HOPA guidance and other recognized oncology resources may inform dosing optimization and application.

    This policy does not require coverage for drugs when the U.S. Food and Drug Administration has determined the use to be contraindicated. In addition, therapies that meet the policy's definition of investigational are excluded from coverage. Providers requesting coverage for off‑label uses should be aware that such requests must meet the policy's evidentiary standards (see investigational and off‑label criteria) to be considered non‑investigational and eligible for benefit determination.

    A medication or technology is considered investigational and not covered when it fails to meet Blue Cross of Idaho's required criteria. Specifically, the product must have final approval from the appropriate regulatory body (interim approval is insufficient) for the same condition under review; there must be sufficient peer‑reviewed scientific evidence permitting conclusions about effects on health outcomes; the benefits must outweigh harms and be at least as good as established alternatives; and demonstrated improvements must be reproducible in usual clinical practice. For off‑label drug uses not found in recognized references, at least two peer‑reviewed studies supporting efficacy and safety must be submitted and will be evaluated on their strength of evidence before the use can be considered non‑investigational.

    Prior Authorization & Provider Requirements

    Prior Authorization

    Submit prior authorization for PA‑listed medications

    All medications listed on the Blue Cross of Idaho prior authorization list must undergo the prior authorization process before coverage will be approved.

    Step Therapy

    Provide trial/failure of formulary therapeutic equivalents

    When a formulary exception is sought (where the contract allows), provide evidence that the member has tried and failed formulary therapeutic equivalents or that those equivalents are expected to cause harm; utilization management rules for drugs in the same therapeutic class will also be applied as applicable.

    • Requested medication must be for an FDA‑approved indication.
    • Medication and dose must be medically necessary and appropriate.
    • Document that all available therapeutic equivalents on formulary were ineffective or are expected to cause harm.
    • Meet any applicable utilization management requirements for the therapeutic class.
    Documentation Required

    Submit required clinical documentation

    Provide appropriate clinical documentation demonstrating member eligibility under the benefit plan and clinical justification for the request; for formulary exception requests include documentation that therapeutic equivalents were tried and found ineffective or contraindicated.

    • Evidence of member eligibility per the member contract.
    • Clinical information supporting medical necessity or investigational status per contract criteria.
    • For formulary exceptions: documentation that therapeutic equivalents were ineffective or expected to cause harm.
    Denial Risk

    Denial risks: non‑coverage, lack of medical necessity, or missing documentation

    Requests may be denied if the medication is not covered under the member's benefit plan, medical necessity is not demonstrated, or required clinical documentation is not provided.

    • Medication not on the member's benefit plan (non‑covered).
    • Insufficient demonstration of medical necessity or investigational exclusion per contract.
    • Missing or incomplete clinical documentation to support the request.

    Step Therapy / Therapeutic Trial Requirements

    RequirementDetails / DocumentationCoverage Label
    FDA‑approved indication
    Requested medication must be used for an FDA‑approved indication.
    Formulary exception requires trial and failure of formulary therapeutic equivalents when contract allows; documentation that equivalents were ineffective or expected to cause harm must be provided.
    The prescribing provider must document that all available therapeutic equivalents on the formulary (or other medically appropriate medications if no equivalents exist) either: (a) were ineffective for the condition OR (b) are reasonably expected to cause a harmful or adverse clinical reaction or response.
    Utilization management
    The requested drug must meet any applicable utilization management requirements if it is in the same therapeutic class as formulary drugs that require such authorization.
    Submission
    Formulary exception requests (when contractually allowed) may be submitted using the Formulary Exception Request form.

    Background and Evidence Sources

    Blue Cross of Idaho evaluates medications for medical necessity using evidence-based sources, including FDA approvals and guidance, recognized clinical compendia such as NCCN, and established utilization criteria (InterQual, PBM criteria), as well as peer‑reviewed literature. Off‑label uses may be considered when they meet BCI medical necessity standards and are supported by recognized references (NCCN, AHFS, Facts & Comparisons) or by a minimum of two peer‑reviewed studies when not present in those resources. Oncologic drugs are assessed using NCCN recommendations, with NCCN category 1 or 2A guidance considered medically necessary when appropriately applied.

    Key Definitions

    Medically Necessary — definition and criteria for services/supplies
    DefinitionCovered services or supplies required to identify or treat an insured's condition, disease, illness or accidental injury as recommended by the treating provider and determined by Blue Cross of Idaho.
    Appropriate level of careThe most appropriate supply or level of service considering potential benefits and harms to the insured.
    Evidence of effectivenessProven to be effective in improving health outcomes; for new treatments effectiveness is determined by scientific evidence; for existing treatments by scientific evidence, then professional standards, then expert opinion.
    Not for convenienceNot primarily for the convenience of the insured or covered provider.
    Cost-effectivenessCost-effective for the condition compared to alternative treatments, including no treatment (cost-effectiveness does not necessarily mean lowest price).
    Investigational — definition and criteria
    DefinitionAny technology (service, supply, procedure, treatment, drug, device, facility, equipment or biological product) in a developmental stage or not proven to improve health outcomes (length/quality of life, functional ability).
    Regulatory approval requirementMust have final approval from the appropriate government regulatory body (e.g., FDA) for the specific condition being evaluated; interim approval is not sufficient.
    Evidence standardScientific evidence must permit conclusions concerning the effect on health outcomes, based on current published medical literature and peer‑reviewed investigations; study quality and consistency are considered.
    Net health outcomeTechnology must demonstrate that beneficial effects on health outcomes outweigh harmful effects.
    Comparative benefit and generalizabilityMust be as beneficial as established alternatives and show improvement attainable under usual conditions of medical practice.
    Policy Summary
    PayerBluecross Idaho
    PolicyGuidelines for Prior Authorization of Pharmacologic Therapies
    Policy CodePolicy MP 5.01.501
    Change TypeNo material changes
    Effective DateDec 18, 2025
    Last ReviewDec 18, 2025
    Next Review DateDec 18, 2025
    Key ActionSubmit prior authorization for any medication on the Blue Cross of Idaho PA list.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaPrior Authorization & Provider RequirementsStep Therapy / Therapeutic Trial RequirementsBackground and Evidence SourcesKey Definitions